Home Cart Sign in  
Chemical Structure| 1627494-13-6 Chemical Structure| 1627494-13-6
Chemical Structure| 1627494-13-6

AZD8186

CAS No.: 1627494-13-6

AZD8186 is an isoform-specific small-moleculePI3K inhibitor, potently inhibits PI3Kβ (IC50=4 nM) and PI3Kδ (IC50=12 nM) with selectivity over PI3Kα (IC50=35 nM) and PI3Kγ (IC50=675 nM).

Synonyms: AZD8186

4.5 *For Research Use Only !

Cat. No.: A160272 Purity: 99%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÇʶÊÊ Inquiry Inquiry
5mg łÇ§¶ÊÊ Inquiry Inquiry
10mg łÇò¶ÊÊ Inquiry Inquiry
25mg łËͶÊÊ Inquiry Inquiry
50mg ł§ÿ¶ÊÊ Inquiry Inquiry
100mg łÿÿ¶ÊÊ Inquiry Inquiry
250mg łòò¶ÊÊ Inquiry Inquiry
1g łÇîÿ¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łÇʶÊÊ

  • 5mg

    łÇ§¶ÊÊ

  • 10mg

    łÇò¶ÊÊ

  • 25mg

    łËͶÊÊ

  • 50mg

    ł§ÿ¶ÊÊ

  • 100mg

    łÿÿ¶ÊÊ

  • 250mg

    łòò¶ÊÊ

  • 1g

    łÇîÿ¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of AZD8186

CAS No. :1627494-13-6
Formula : C24H25F2N3O4
M.W : 457.47
SMILES Code : O=C(C1=CC(C(C=C(N2CCOCC2)O3)=O)=C3C([C@H](NC4=CC(F)=CC(F)=C4)C)=C1)N(C)C
Synonyms :
AZD8186
InChI Key :LMJFJIDLEAWOQJ-CQSZACIVSA-N
Pubchem ID :52913813

Safety of AZD8186

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of AZD8186

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110β

    PI3Kβ, IC50:4 nM

  • p110α

    PI3Kα, IC50:35 nM

  • p110δ

    PI3Kδ, IC50:12 nM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
MDA-MB-468 0.5 µM 1, 3, 6, and 24 hours To assess the effect of PI3K β inhibition on metabolic pathway activities in a PTEN null breast cancer cell line, the results showed that AZD8186 significantly altered 286 isotope-enriched features, of which 19 features could be attributed to known targeted pathways. PMC9614656
HCC70 100 nM 14-21 days To screen for genes conferring resistance to the PI3Kβ inhibitor AZD8186 PMC9652152
EVSA-T 250 nM 14-21 days To screen for genes conferring resistance to the PI3Kβ inhibitor AZD8186 PMC9652152
ZR-75-1 50 nM 14-21 days To screen for genes conferring resistance to the PI3Kβ inhibitor AZD8186 PMC9652152
LNCaP 25 nM 2 hours AZD8186 at 25 nM significantly inhibited Akt phosphorylation in LNCaP cells PMC4293347
HT 0.5 µM 24 hours Induced G0/G1 cell cycle arrest PMC9883168
K422 0.5 µM 24 hours Induced G0/G1 cell cycle arrest PMC9883168
KYSE70 cells 3μg/ml, 30μg/ml 24 hours To evaluate cell apoptosis and cell cycle distribution, results showed AZD8186 induced cell apoptosis and G1 phase arrest. PMC6648684
MKN45 and MKN28 gastric cancer cells 0, 10, 50, 100, 200, 500 μM 24 hours and 48 hours To evaluate the inhibitory effect of AZD8186 on gastric cancer cells, the results showed that AZD8186 exhibited a dose-dependent inhibitory effect on MKN45 and MKN28 cells after 24 and 48 hours. PMC11220201
BT-549 250 nM 30 minutes AZD8186 at 250 nM significantly inhibited Akt phosphorylation in BT-549 cells within 30 minutes PMC4293347
OCI-Ly10 0.5 µM 48 hours Induced apoptosis PMC9883168
TMD8 0.5 µM 48 hours Induced apoptosis PMC9883168
Riva 0.5 µM 48 hours Induced apoptosis PMC9883168
A2780 4.88 to 13.39 µM 48 hours To evaluate the inhibitory effect of AZD8186 on A2780 cells, the results showed that PI3KCA-mutated cells were more sensitive to AZD8186. PMC7063971
A2780CP70 4.88 to 13.39 µM 48 hours To evaluate the inhibitory effect of AZD8186 on A2780CP70 cells, the results showed that PI3KCA-mutated cells were more sensitive to AZD8186. PMC7063971
HAC-2 4.88 to 13.39 µM 48 hours To evaluate the inhibitory effect of AZD8186 on HAC-2 cells, the results showed that PI3KCA-mutated cells were more sensitive to AZD8186. PMC7063971
Daoy cells 1 µM 6 hours Inhibition of PI3K/AKT/mTOR signaling pathway, detection of SOX9 protein degradation PMC5069553
DU145-DR 5 µM 72 h AZD8186 alone strongly suppressed AKT and GSK3 β phosphorylation and, to a lesser degree, S6 phosphorylation. PMC10838968
PC3-DR 5 µM 72 h AZD8186 alone strongly suppressed AKT and GSK3 β phosphorylation and, to a lesser degree, S6 phosphorylation. PMC10838968
BT-474 250 nM AZD8186 at 250 nM had no significant effect on Akt/mTOR signaling in BT-474 cells PMC4293347
HNSCC cells 1.5 µM AZD8186 enhances radio- and radiochemosensitivity in the majority of HNSCC cell models, independent of PIK3CA mutation status PMC11627550

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Mice LNCaP xenograft model EC50 75 mg/kg Single dose AZD8186 at a single dose of 75 mg/kg significantly inhibited Akt signaling in the LNCaP xenograft model, but the signaling rebounded after 8 hours PMC4293347
Mice OCI-Ly10 and K422 xenograft models 50 mg/kg Daily, for 35 days Combination of AZD8186 and AZD2014 significantly reduced tumor growth PMC9883168
Nude mice HCC70 and PC3 xenograft models Oral 25 mg/kg or 50 mg/kg Single dose or every 12 hours for 1 week To evaluate the inhibitory effects of AZD8186 on AKT and rpS6 phosphorylation. In the HCC70 xenograft model, AZD8186 suppressed phosphorylation of AKT1, AKT2, and rpS6 for 4 to 7 hours post-single dose, but levels returned to baseline by 24 hours. In the PC3 xenograft model, AZD8186 suppressed phosphorylation of AKT3 at all doses tested. PMC8026683
BALB/c (nu/nu) mice DU145-DR xenograft model Oral 40 mg/kg Twice daily for 18 days The combination of AZD8186 with selumetinib significantly reduced tumor growth without showing toxicity. PMC10838968
Nude-Foxn1nu mice HCC70 tumor xenograft model Oral 66.6 mg/kg Once daily for 7 days To evaluate the anti-tumor activity of AZD8186 in combination with AZD5991 PMC9652152
Nude mice KYSE70 esophageal cancer xenograft model tail vein injection 10mg/kg every three days for 21 days To evaluate the anti-tumor efficacy of AZD8186-DCM and DTX-DCM combination therapy, results showed that the combination therapy significantly inhibited tumor growth. PMC6648684
NOD/SCID mice NOD/SCID mice Oral 25 or 50 mg/kg twice daily, 5 days on, 2 days off To evaluate the inhibitory effect of AZD8186 on tumor growth in mice, the results showed that AZD8186 significantly inhibited the growth of ES2 tumors. PMC7063971

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.19mL

0.44mL

0.22mL

10.93mL

2.19mL

1.09mL

21.86mL

4.37mL

2.19mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories